Smith J M
Allergol Immunopathol (Madr). 1975 Jan-Feb;3(1):29-34.
Disodium cromoglycate has been shown experimentally and by clinical trials to be a useful addition to available treatment for asthma. Follow jp studies have shown no loss of effect with continuous use. Bronchodilators and steroid treatment is used less, resulting in benefits in the overall safety of treatment. Studies of patients treated for more than three years continuously have failed to show evidence of toxic effects. The greatest dangers associated with cromoglycate are failure of some patients to continue treatment as instructed and the possibility of temporary loss of effect during acute attacks of asthma when no inhaled treatment can be effective and systemic treatment is essential. The method of action of disodium cromoglycate is the stabilisation of mast cells resulting in a less ready release of mediator substances, thus causing a reduced asthmatic response. This protective effect could not be obtained after challenge, but it is present if the drug was inhaled prior to challenge. Disodium cromoglycate has been shown experimentally and by clinical trials to be a useful addition to available treatment for asthma. Follow up studies have shown no loss of effect with continuous use. Bronchodilators and steroid treatment is used less, resulting in benefits in the overall safety of treatment. Studies of patients treated for more than three years continuously have failed to show evidence of toxic effects. The greatest dangers associated with cromoglycate are failure of some patients to continue treatment as instructed and the possibility of temporary loss of effect during acute attacks of asthma when no inhaled treatment can be effective and systemic treatment is essential. A study carried out on 242 children showed that 65% clearly benefited from cromoglycate and 57 out of 96 who were on continuous steroid therapy were able to discontinue the steroid treatment. Recently, 998 patients treated with cromoglycate were reviewed for evidence of toxic effects. The most serious side effects observed were hoarse voice due to larynx irritation caused by the inhaled powder, clearing up after discontinuation of the drug. Severe cases of asthma controlled with cromoglycate or any toher inhaled therapy may experience relapses, which could be managed by a prompt systemic treatment.
实验研究和临床试验均表明,色甘酸钠是现有哮喘治疗方法的有益补充。后续研究表明,持续使用不会导致药效丧失。支气管扩张剂和类固醇治疗的使用减少,从而提高了治疗的整体安全性。对连续治疗三年以上的患者进行的研究未发现有毒性作用的证据。与色甘酸钠相关的最大风险是,一些患者未按医嘱持续治疗,以及在哮喘急性发作期间可能出现暂时失效的情况,此时吸入治疗无效,全身治疗必不可少。色甘酸钠的作用机制是稳定肥大细胞,减少介质物质的释放,从而减轻哮喘反应。激发后无法获得这种保护作用,但在激发前吸入该药物则可产生保护作用。实验研究和临床试验均表明,色甘酸钠是现有哮喘治疗方法的有益补充。后续研究表明,持续使用不会导致药效丧失。支气管扩张剂和类固醇治疗的使用减少,从而提高了治疗的整体安全性。对连续治疗三年以上的患者进行的研究未发现有毒性作用的证据。与色甘酸钠相关的最大风险是,一些患者未按医嘱持续治疗,以及在哮喘急性发作期间可能出现暂时失效的情况,此时吸入治疗无效,全身治疗必不可少。一项针对242名儿童的研究表明,65%的儿童明显从色甘酸钠治疗中获益,在96名持续接受类固醇治疗的儿童中,有57名能够停止使用类固醇药物。最近,对998名接受色甘酸钠治疗的患者进行了毒性作用审查。观察到的最严重副作用是吸入粉末刺激喉部导致声音嘶哑,停药后症状消失。使用色甘酸钠或任何其他吸入疗法控制的严重哮喘病例可能会复发,可通过及时的全身治疗进行处理。